Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

被引：95

作者：

Zaman, K. ^{[1
]}

Sack, D. A. ^{[1
]}

Yunus, M. ^{[1
]}

Arifeen, S. E. ^{[1
]}

Podder, G. ^{[1
]}

Azim, T. ^{[1
]}

Luby, S. ^{[1
]}

Breiman, R. F. ^{[1
]}

Neuzil, K. ^{[2
]}

Datta, S. K. ^{[3
]}

Delem, A. ^{[3
]}

Suryakiran, P. V. ^{[3
]}

Bock, H. L. ^{[3
]}

机构：

[1] ICDDR B, Dhaka 1000, Bangladesh

[2] PATH Rotavirus Vaccine Program, Seattle, WA USA

[3] GlaxoSmithKline Biol, Rixensart, Belgium

来源：

VACCINE | 2009年 / 27卷 / 09期

关键词：

Rotavirus; Vaccine; Gastrointestinal disease; Oral poliovirus; EFFICACY; DISEASE; LIVE; IMMUNOGENICITY; DEATHS; SAFETY;

D O I：

10.1016/j.vaccine.2008.12.059

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix (TM)) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age): or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rites. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：1333 / 1339

页数：7

共 24 条

[1] Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial [J].

Bernstein, DI ;

Sack, DA ;

Rothstein, E ;

Reisinger, K ;

Smith, VE ;

O'Sullivan, D ;

Spriggs, DR ;

Ward, RL .

LANCET, 1999, 354 (9175) :287-290

[2] Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12 [J].

Bernstein, DI ;

Smith, VE ;

Sherwood, JR ;

Schiff, GM ;

Sander, DS ;

DeFeudis, D ;

Spriggs, DR ;

Ward, RL .

VACCINE, 1998, 16 (04) :381-387

[3]

BOSE A, 2007, P 5 WORLD C PED INF

[4] Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh [J].

Bresee, JS ;

El Arifeen, S ;

Azim, T ;

Chakraborty, J ;

Mounts, AW ;

Podder, G ;

Gentsch, JR ;

Ward, RL ;

Black, R ;

Glass, RI ;

Yunus, M .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (12) :1136-1143

[5]

DEVOS B, 2006, P INT C ANT AG CHEM

[6]

Estes M.K., 2007, Fields Virology, V2, P1917

[7] Serotype diversity and reassortment between human and animal rotavirus strains:: Implications for rotavirus vaccine programs [J].

Gentsch, JR ;

Laird, AR ;

Bielfelt, B ;

Griffin, DD ;

Bányai, K ;

Ramachandran, M ;

Jain, V ;

Cunliffe, NA ;

Nakagomi, O ;

Kirkwood, CD ;

Fischer, TK ;

Parashar, UD ;

Bresee, JS ;

Jiang, B ;

Glass, RI .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 :S146-S159

[8]

Kapikian A.Z., 2001, FIELDS VIROLOGY, V4th, P1787

[9] Rotavirus vaccine RIX4414 (Rotarix™) [J].

Keating G.M. .

Pediatric Drugs, 2006, 8 (6) :389-395

[10]

Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197

← 1 2 3 →